- Resource Centers
Amlodipine Besylate and Benazepril HCl Capsules
Marketed by: Lupin Pharmaceuticals, Inc (Baltimore, MD)
Compared to: Lotrel (Novartis)
Indication: Lupin Pharmaceuticals, Inc received final FDA approval on July 6, 2011, for its Amlodipine Besylate/Benazepril HCl 5-mg/40-mg and 10-mg/40-mg capsules. This approval completes the product line, as the company was granted final approval for Amlodipine/Benazepril 2.5-mg/10-mg, 5-mg/10-mg, 5-mg/20-mg, and 10-mg/20-mg capsules in February 2010. Lupin’s Amlodipine/ Benazepril capsules are the AB-rated generic equivalent of Novartis’ Lotrel capsules, and are indicated for the treatment of hypertension.
Dosage Form: Capsules, amlodipine/benazepril: 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg, and 10 mg/40 mg
For More Information: www.lupinpharmaceuticals.com; 866-587-4617
Levofloxacin Oral Solution
Marketed by: Hi-Tech Pharmacal Co Inc (Amityville, NY)
Compared to: Levaquin Oral Solution (PriCara, a division of Ortho-McNeil-Janssen Pharmaceuticals)
Indication: Hi-Tech Pharmacal’s Levofloxacin Oral Solution is an AA-rated generic equivalent to PriCara’s Levaquin Oral Solution. Levofloxacin Oral Solution is a fluroquinolone antibacterial indicated for patients 18 years or older with infections caused by designated, susceptible bacteria. The typical dosage is 250, 500, or 750 mg administered orally every 24 hours, depending on the infection being treated. Dosage adjustments are necessary in patients with impaired renal function (creatinine clearance <50 mL/min). Fluroquinolones, including Levofloxacin Oral Solution, are associated with an increased risk of tendonitis and tendon rupture, and may exacerbate muscle weakness in patients with myasthenia gravis.
Dosage Form: Oral solution: each mL contains 25 mg of levofloxacin. Levofloxacin Oral Solution 25 mg/mL is available in multiple sizes—480 mL, 200 mL, and 100 mL.
For More Information: www.hitechpharm.com
Levetiracetam Extended-Release Tablets
Marketed by: Teva Pharmaceuticals (North Wales, PA)
Compared to: Keppra XR (UCB)
Indication: The FDA approved Teva’s levetiracetam extended-release tablets, an AB-rated bioequivalent generic version of Keppra XR. Levetiracetam is an anticonvulsant indicated in combination with other medications to treat partial onset seizures. The oncedaily formulation is approved for patients 16 years and older who have epilepsy. The recommended initial dose of levetiracetam extended-release tablets is 1000 mg, taken once daily. Physicians may choose to increase the daily dosage in increments of 1000 mg every 2 weeks to a maximum of 3000 mg. Patients should swallow the tablets whole and not chew, cut, or crush them. Due to the risk of behavioral side effects associated with all antiepileptic medications, patients taking levetiracetam should be closely monitored for signs of depression or mood changes.
Dosage Form: Extended-release tablets: 500 and 750 mg
For More Information: www.tevausa.com; 888-838-2872